SciClone Could Pay SEC $12.8 Million in FCPA Case
SciClone Pharmaceuticals has disclosed in a quarterly report that it’s discussing a tentative $12.8 million settlement with the Securities and Exchange Commission to resolve an investigation of potential violations of the Foreign Corrupt Practices Act with respect to its China operations. Details inside.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
PremiumGlencore compliance monitorships ended early by DOJ
The U.S. Department of Justice ended two compliance monitorships on Glencore International more than a year early, monitorships imposed in 2022 after the company was convicted of paying bribes and manipulating commodities markets.
-
News BriefCalifornia Attorney General Bonta warns businesses that FCPA still in full force
The federal government may have paused enforcement of the Foreign Corrupt Practices Act (FCPA), but that’s not the case in California, where bribes to foreign officials will be prosecuted, Attorney General Rob Bonta warned.
-
PremiumAs DOJ pivots away from white-collar enforcement, is FCPA still relevant?
While executives and boards will never conclude that bribery is a legitimate way of doing business, understandably many have questions about how to direct their FCPA compliance program efforts and resources, write Iris Bennett and Claire Rajan, partners at law firm Steptoe.